Shanghai Junshi Biosciences Past Earnings Performance
Past criteria checks 0/6
Shanghai Junshi Biosciences's earnings have been declining at an average annual rate of -24.4%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 14.3% per year.
Key information
-24.4%
Earnings growth rate
-17.9%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 14.3% |
| Return on equity | -31.3% |
| Net Margin | -124.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth
May 06
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Mar 22Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%
Jan 26Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Dec 17Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?
Nov 20Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?
Sep 05Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
May 22Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate
May 01A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Jan 16Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 03Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Oct 12A Look At The Fair Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Jul 05Revenue & Expenses BreakdownBeta
How Shanghai Junshi Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,628 | -2,023 | 1,414 | 1,686 |
| 31 Dec 23 | 1,503 | -2,283 | 1,399 | 1,937 |
| 30 Sep 23 | 1,222 | -2,200 | 1,267 | 2,019 |
| 30 Jun 23 | 1,177 | -2,473 | 1,293 | 2,271 |
| 31 Mar 23 | 1,079 | -2,535 | 1,243 | 2,401 |
| 31 Dec 22 | 1,453 | -2,388 | 1,285 | 2,384 |
| 30 Sep 22 | 2,525 | -1,924 | 1,355 | 2,282 |
| 30 Jun 22 | 2,856 | -1,643 | 1,259 | 2,184 |
| 31 Mar 22 | 3,039 | -1,495 | 1,284 | 2,129 |
| 31 Dec 21 | 4,025 | -721 | 1,377 | 2,069 |
| 30 Sep 21 | 3,302 | -945 | 1,388 | 1,991 |
| 30 Jun 21 | 3,134 | -1,060 | 1,471 | 2,016 |
| 31 Mar 21 | 3,038 | -1,062 | 1,410 | 2,011 |
| 31 Dec 20 | 1,595 | -1,669 | 1,127 | 1,778 |
| 30 Sep 20 | 1,259 | -1,418 | 871 | 1,543 |
| 30 Jun 20 | 1,041 | -1,056 | 707 | 1,286 |
| 31 Mar 20 | 868 | -600 | 609 | 968 |
| 31 Dec 19 | 775 | -747 | 537 | 946 |
| 30 Sep 19 | 528 | -732 | 429 | 802 |
| 30 Jun 19 | 310 | -735 | 298 | 689 |
| 31 Mar 19 | 79 | -992 | 203 | 662 |
| 31 Dec 18 | 1 | -717 | 146 | 538 |
| 30 Sep 18 | 0 | -516 | 104 | 453 |
| 30 Jun 18 | 0 | -439 | 94 | 377 |
| 31 Mar 18 | 0 | -347 | 79 | 289 |
| 31 Dec 17 | 1 | -321 | 74 | 275 |
| 30 Sep 17 | 9 | -279 | 104 | 172 |
| 30 Jun 17 | 5 | -246 | 22 | 239 |
| 31 Mar 17 | 9 | -191 | 156 | 58 |
| 31 Dec 16 | 4 | -131 | 42 | 122 |
| 30 Sep 16 | 4 | -109 | 138 | 0 |
| 30 Jun 16 | 2 | -83 | 110 | 0 |
| 31 Mar 16 | 2 | -71 | 97 | 0 |
| 31 Dec 15 | 3 | -58 | 84 | 0 |
| 30 Sep 15 | 5 | -43 | 70 | 0 |
| 30 Jun 15 | 7 | -27 | 57 | 0 |
| 31 Mar 15 | 6 | -26 | 50 | 0 |
| 31 Dec 14 | 6 | -25 | 44 | 0 |
Quality Earnings: 1877 is currently unprofitable.
Growing Profit Margin: 1877 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1877 is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare 1877's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1877 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 1877 has a negative Return on Equity (-31.28%), as it is currently unprofitable.